Recommended Starting Doses for Psoriatic Arthritis After Multiple Treatment Failures
For secukinumab, start with 300 mg subcutaneously at weeks 0,1,2,3, and 4, followed by 300 mg every 4 weeks; for ixekizumab, start with 160 mg subcutaneously followed by 80 mg at weeks 2,4,6,8,10, and 12, then 80 mg every 4 weeks. 1
Secukinumab Dosing Algorithm
The 300 mg dose is specifically recommended for patients who are anti-TNF inadequate responders 2, which directly applies to your patient who has failed two TNF inhibitors. The AAD-NPF guidelines provide Grade A evidence supporting this dosing strategy 1.
Loading Phase (Weeks 0-4):
- 300 mg subcutaneous injection weekly for 5 doses (weeks 0,1,2,3,4)
- This can be given as two 150 mg injections or one 300 mg injection 2
Maintenance Phase (Week 4 onwards):
- 300 mg every 4 weeks 1
- The 300 mg dose demonstrates superior efficacy compared to 150 mg, particularly in TNF-inadequate responders 1, 3
Critical caveat: While 150 mg is the standard dose for most PsA patients, the 300 mg dose is specifically indicated for those with inadequate response to TNF inhibitors 2. Meta-analysis data confirms that secukinumab 300 mg achieves significantly higher ACR20, ACR50, and PASI 75 response rates than 150 mg, especially in the anti-TNF-IR subgroup 3.
Ixekizumab Dosing Algorithm
Loading Phase (Weeks 0-12):
- 160 mg subcutaneous injection at week 0 (starting dose)
- 80 mg at weeks 2,4,6,8,10, and 12 1
Maintenance Phase (Week 12 onwards):
The AAD-NPF guidelines provide Grade A strength recommendations for this dosing regimen in PsA patients 1. Ixekizumab has demonstrated efficacy in patients with inadequate response to one or two TNF inhibitors, with sustained improvement through 52 weeks 4.
Key Clinical Considerations
For your specific patient context (failed 2 TNF inhibitors + 1 JAK inhibitor):
- Both IL-17 inhibitors are appropriate choices after multiple treatment failures 5
- Secukinumab 300 mg may have an edge given the specific evidence for superior efficacy in TNF-inadequate responders 3, 6, 7
- Network meta-analysis suggests secukinumab 300 mg ranks highest for ACR20 response in TNF-IR patients, followed by ixekizumab 80 mg Q2W 6
Safety profile: Both agents show comparable safety with no significant increase in serious adverse events compared to placebo 3, 6. Monitor for infections, particularly mucocutaneous candidiasis with secukinumab 2.
Common pitfall to avoid: Do not use the 150 mg dose of secukinumab in TNF-inadequate responders expecting equivalent results—the 300 mg dose is specifically indicated and more effective in this population 2, 3.